Abstract
Zinc finger protein, X-linked (ZFX) mediates the development and progression of human cancers. However, its potential role in chronic myeloid leukemia (CML) is still unknown. The ZFX expression was significantly increased in CML patients and cell lines. Based on loss-of-function experiments in CML cells, we found that knockdown of ZFX expression impaired cell proliferation and induced mitotic arrest in G0/G1 stage and apoptosis. In addition, ZFX silencing sensitized CML cells to imatinib treatment. Further, phospho-Akt (p-Akt), CyclinD1, CyclinE1, and Bcl-2 were downregulated, and Caspase-3 was upregulated in ZFX-silenced cells. In summary, our data suggest that ZFX is a novel oncogene promoting cell proliferation and inducing imatinib resistance via PI3K/Akt signaling pathway. ZFX may represent a potential therapeutic target in CML.
Similar content being viewed by others
References
Apperley, J. F. (2015). Chronic myeloid leukaemia. Lancet, 385(9976), 1447–1459.
Ren, R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer, 5(3), 172–183.
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004). JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 18(2), 189–218.
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine, 344(14), 1031–1037.
Kantarjian, H. M., Cortes, J. E., O’Brien, S., Giles, F., Garcia-Manero, G., Faderl, S., et al. (2003). Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: High incidence of early complete and major cytogenetic responses. Blood, 101(1), 97–100.
Hochhaus, A., Kreil, S., Corbin, A. S., La Rosee, P., Muller, M. C., Lahaye, T., et al. (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16(11), 2190–2196.
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013). Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: A clinical perspective and emerging treatment options. Clinical Lymphoma Myeloma and Leukemia, 13(5), 515–529.
Laity, J. H., Lee, B. M., & Wright, P. E. (2001). Zinc finger proteins: New insights into structural and functional diversity. Current Opinion in Structural Biology, 11(1), 39–46.
Poloumienko, A. (2004). Cloning and comparative analysis of the bovine, porcine, and equine sex chromosome genes ZFX and ZFY. Genome Génome/Conseil National De Recherches Canada, 47(1), 74–83.
Cellot, S., & Sauvageau, G. (2007). Zfx: At the crossroads of survival and self-renewal. Cell, 129(2), 239–241.
Galan-Caridad, J. M., Harel, S., Arenzana, T. L., Hou, Z. E., Doetsch, F. K., Mirny, L. A., et al. (2007). Zfx controls the self-renewal of embryonic and hematopoietic stem cells. Cell, 129(2), 345–357.
Harel, S., Tu, E. Y., Weisberg, S., Esquilin, M., Chambers, S. M., Liu, B., et al. (2012). ZFX controls the self-renewal of human embryonic stem cells. PLoS One, 7(8), e42302.
Jiang, H., Zhang, L., Liu, J., Chen, Z., Na, R., Ding, G., et al. (2012). Knockdown of zinc finger protein X-linked inhibits prostate cancer cell proliferation and induces apoptosis by activating caspase-3 and caspase-9. Cancer Gene Therapy, 19(10), 684–689.
Jiang, M., Xu, S., Yue, W., Zhao, X., Zhang, L., Zhang, C., et al. (2012). The role of ZFX in non-small cell lung cancer development. Oncology Research, 20(4), 171–178.
Wu, S., Lao, X. Y., Sun, T. T., Ren, L. L., Kong, X., Wang, J. L., et al. (2013). Knockdown of ZFX inhibits gastric cancer cell growth in vitro and in vivo via downregulating the ERK-MAPK pathway. Cancer Letters, 337(2), 293–300.
Zhu, Z., Li, K., Xu, D., Liu, Y., Tang, H., Xie, Q., et al. (2013). ZFX regulates glioma cell proliferation and survival in vitro and in vivo. Journal of Neuro-oncology, 112(1), 17–25.
Yang, H., Lu, Y., Zheng, Y., Yu, X., Xia, X., He, X., et al. (2014). shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells. Cancer Chemotherapy and Pharmacology, 73(3), 569–576.
Weisberg, S. P., Smith-Raska, M. R., Esquilin, J. M., Zhang, J., Arenzana, T. L., Lau, C. M., et al. (2014). ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia. Cell Reports, 6(3), 528–540.
Qi, J., Peng, H., Gu, Z. L., Liang, Z. Q., & Yang, C. Z. (2004). Establishment of an imatinib resistant cell line K562/G01 and its characterization. Zhonghua Xue Ye Xue Za Zhi, 25(6), 337–341.
Conde, I., Pabon, D., Jayo, A., Lastres, P., & Gonzalez-Manchon, C. (2010). Involvement of ERK1/2, p38 and PI3K in megakaryocytic differentiation of K562 cells. European Journal of Haematology, 84(5), 430–440.
Yin, J., Jiang, Y., Wu, H., Wang, J., Zhang, S., & Liu, H. (2015). Overexpression of ZFX and its involvement in squamous cell carcinoma of the tongue. Oncology Reports, 33(1), 141–148.
Lai, K. P., Chen, J., He, M., Ching, A. K., Lau, C., Lai, P. B., et al. (2014). Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma. International Journal of Cancer, 135(8), 1790–1799.
Li, K., Zhu, Z. C., Liu, Y. J., Liu, J. W., Wang, H. T., Xiong, Z. Q., et al. (2013). ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299. International Journal of Clinical and Experimental Pathology, 6(11), 2460–2467.
Fang, Q., Fu, W. H., Yang, J., Li, X., Zhou, Z. S., Chen, Z. W., et al. (2014). Knockdown of ZFX suppresses renal carcinoma cell growth and induces apoptosis. Cancer Genetics, 207(10–12), 461–466.
Zhang, H., Chang, G., Wang, J., Lin, Y., Ma, L., & Pang, T. (2013). CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment. Leukemia Research, 37(11), 1583–1591.
Wang, H., Yu, J., Zhang, L., Xiong, Y., Chen, S., Xing, H., et al. (2014). RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells. Biochemical and Biophysical Research Communications, 446(4), 1204–1210.
Wang, Y., Jiang, Y., Bian, C., Dong, Y., Ma, C., Hu, X., et al. (2015). Overexpression of Hiwi inhibits the cell growth of chronic myeloid leukemia K562 cells and enhances their chemosensitivity to daunomycin. Cell Biochemistry and Biophysics, 73(1), 129–135.
Fang, J., Yu, Z., Lian, M., Ma, H., Tai, J., Zhang, L., et al. (2012). Knockdown of zinc finger protein, X-linked (ZFX) inhibits cell proliferation and induces apoptosis in human laryngeal squamous cell carcinoma. Molecular and Cellular Biochemistry, 360(1–2), 301–307.
Palmer, C. J., Galan-Caridad, J. M., Weisberg, S. P., Lei, L., Esquilin, J. M., Croft, G. F., et al. (2014). Zfx facilitates tumorigenesis caused by activation of the Hedgehog pathway. Cancer Research, 74(20), 5914–5924.
Burchert, A., Wang, Y., Cai, D., von, B. N., Paschka, P., Muller-Brusselbach, S., et al. (2005). Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia, 19(10), 1774–1782.
Author information
Authors and Affiliations
Corresponding author
Additional information
Jingjing Wu and Bin Wei have contributed equally to this work and should be considered co-first authors.
Rights and permissions
About this article
Cite this article
Wu, J., Wei, B., Wang, Q. et al. ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells. Cell Biochem Biophys 74, 277–283 (2016). https://doi.org/10.1007/s12013-016-0725-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-016-0725-x